We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Differential Production of Amyloid Proteins Marks Hereditary Alzheimer's Disease

By LabMedica International staff writers
Posted on 24 Jun 2013
Alzheimer's disease (AD) researchers employing SILK (stable isotope linked kinetics) technology have shown that individuals with a hereditary form of AD overproduce type 42 amyloid beta protein, which readily accumulates in the amyloid plaques that characterize the disease.

Most cases of Alzheimer's disease are not hereditary. More...
However, there is a small subset of cases that have an earlier age of onset and a strong genetic element. In patients suffering from this form of Alzheimer's disease (autosomal dominant hereditary), mutations in the presenilin proteins (PSEN1 and PSEN2) or the amyloid precursor protein (APP) can be found. The majority of these cases carry mutant presenilin genes. An important factor in the disease process in AD is the accumulation of amyloid beta (Abeta) protein. To form Abeta, APP must be cut by two enzymes, beta secretases and gamma secretase. Presenilin is the sub-component of gamma secretase that is responsible for the cutting of APP.

Until the development of SILK, there was no method to directly measure the production or clearance of Abeta. The SILK technique, which was first described in 2006, requires 36 hours to perform, but is the only published method that allows measurement of amyloid plaque formation and clearance in the living brain.

Investigators at Washington University School of Medicine (St. Louis, MO, USA) recently used SILK technology to evaluate 11 subjects with Alzheimer’s mutations and compare the findings to those obtained from 12 related family members who did not have Alzheimer’s mutations.

Results revealed that the AD patients synthesized about 20% more Abeta42 than did family members who lacked the Alzheimer’s mutation. The fractional turnover rate of soluble Abeta42 relative to another form of amyloid protein Abeta40 was 65% faster in mutation carriers and correlated with amyloid deposition, consistent with increased deposition of Abeta42 into plaques, leading to reduced recovery of Abeta42 in cerebrospinal fluid (CSF).

“These results indicate how much we should target amyloid beta 42 with Alzheimer’s drugs,” said senior author Dr. Randall Bateman, professor of neurology at Washington University School of Medicine. “We are hopeful that this and other research will lead to preventive therapies to delay or even possibly prevent Alzheimer’s disease.”

The study was published in the June 12, 2013, issue of the journal Science Translational Medicine.

Related Links:
Washington University School of Medicine




New
Gold Member
Latex Test
SLE-Latex Test
Serological Pipet Controller
PIPETBOY GENIUS
New
Anti-Thyroid Peroxidase Assay
LIAISON Anti-TPO
New
Silver Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: How the predictive test works (Photo courtesy of QMUL)

World’s First Clinical Test Predicts Best Rheumatoid Arthritis Treatment

Rheumatoid arthritis (RA) is a chronic condition affecting 1 in 100 people in the UK today, causing the immune system to attack its joints. Unlike osteoarthritis, which is caused by wear and tear, RA can... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.